Director of the Early Drug Development Division and Co-Chair for the Experimental Therapeutics Program at the European Institute of Oncology, a comprehensive cancer center in Milan, Italy. He is a steering committee member of the Department of Oncology and Hemato-Oncology at the University of Milan. Moreover, he is a member of the Italian National Health Council, serving as an adviser to the Ministry of Health for cancer policy issues.

Prof. Giuseppe Curigliano has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, BMS, Celcuity, Daiichi Sankyo, Exact Sciences, Menarini, Merck, Novartis, Pfizer, Roche, Ellipsis, Astellas, Blueprint Medicines, BMS, Kymab, Philogen, Relay Therapeutics and Sanofi​